China Provincial FDA Probes Drug Maker Over Herbal Injectable
This article was originally published in PharmAsia News
A Chinese provincial FDA is investigating drug maker Xi'an Jiahui Pharmaceutical over its injectable herbal drug for chronic renal failure. The Shaanxi Province FDA said the company has voluntarily closed its facilities while the probe continues into chills and high fever reported in 23 patients given the drug at a hospital. Two batches of the drug came up positive in a pyrogen reaction test, but an initial investigation suggests the drug maker's production did not violate any laws and that technical problems may have been involved. The two batches were recalled. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.